Literature DB >> 24432781

Hereditary angioedema: a brief review of new developments.

Katherine A Altman1, David R Naimi.   

Abstract

BACKGROUND: Angioedema is a serious medical condition characterized by recurrent non-pitting tissue edema. Hereditary (HAE) forms of this disorder are potentially fatal.
METHODS: PubMED, Up to Date and Cochrane Library databases were used to identify scholarly peer reviewed original research or review articles on angioedema. Search terms used were: angioedema, HAE, ACE inhibitor induced angioedema, acquired angioedema, type III HAE (now termed HAE with normal C1-INH), diagnosis of HAE, and treatment of HAE. Inclusive dates of the search were 1946 through 2013. Articles on urticaria were excluded.
RESULTS: The pathophysiology, clinical manifestations, differential diagnosis and treatments of angioedema are presented. Three variants of HAE are discussed and differentiated from acquired, ACE induced and allergic types of angioedema. Emphasis is placed on understanding that HAE is mediated by bradykinin, not histamine, and is therefore unresponsive to antihistamines, corticosteroids and epinephrine. In contrast, newer therapies that replace C1-INH or block bradykinin production or action are the appropriate treatments for prophylaxis and acute treatment of HAE.
CONCLUSION: Recognition of HAE by primary care providers and distinguishing it from allergic histamine mediated angioedema is essential in preventing recurrent attacks and avoiding inappropriate therapy, and may be life-saving.

Entities:  

Mesh:

Year:  2014        PMID: 24432781     DOI: 10.1185/03007995.2013.879441

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  3 in total

1.  Collaboration for rare disease drug discovery research.

Authors:  Nadia K Litterman; Michele Rhee; David C Swinney; Sean Ekins
Journal:  F1000Res       Date:  2014-10-31

2.  Hereditary Angioedema Type II: First Presentation in Adulthood with Recurrent Severe Abdominal Pain.

Authors:  Mohamed Abuzakouk; Nada AlMahmeed; Esat Memisoglu; Martine McManus; Aydamir Alrakawi
Journal:  Case Reports Immunol       Date:  2018-10-29

3.  Proteomic analysis of intermediate uveitis suggests myeloid cell recruitment and implicates IL-23 as a therapeutic target.

Authors:  Yasir J Sepah; Gabriel Velez; Peter H Tang; Jing Yang; Teja Chemudupati; Angela S Li; Quan D Nguyen; Alexander G Bassuk; Vinit B Mahajan
Journal:  Am J Ophthalmol Case Rep       Date:  2020-03-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.